Indaptus Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020	2019	2018	2017	2016	2015
Market Capitalization	17	15	12	47	14	18	197	59	65	54
Market Cap Growth	-	23.47%	-74.36%	242.87%	-22.21%	-91.09%	233.48%	-9.65%	20.43%	-
Enterprise Value	4	2	-14	8	13	8	156	4	47	23
PE Ratio	-0.96	-0.96	-0.84	-6.06	-3.80	-0.37	-4.51	-2.04	-4.88	-7.55
PB Ratio	1.42	1.22	0.49	1.30	-57.30	1.52	3.67	1.00	2.87	1.53
P/FCF Ratio	-1.10	-1.10	-0.93	-4.31	-4.10	-0.58	-4.49	-2.17	-5.23	-5.82
P/OCF Ratio	-1.10	-1.10	-0.92	-4.14	-4.10	-0.60	-5.03	-2.66	-5.44	-6.83
EV/EBITDA Ratio	-0.10	-0.10	1.00	-1.00	-3.74	-0.18	-3.67	-0.13	-3.52	-3.37
EV/EBIT Ratio	-0.10	-0.10	1.00	-1.00	-3.74	-0.18	-3.60	-0.13	-3.52	-3.37
EV/FCF Ratio	-0.12	-0.12	1.11	-0.71	-4.03	-0.28	-3.57	-0.14	-3.76	-2.52
Debt / Equity Ratio	0.01	0.01	0.00	0.00	-5.96	0.07	-	-	-	-
Debt / EBITDA Ratio	-0.01	-0.01	-0.01	-0.02	-0.40	-0.02	-	-	-	-
Debt / FCF Ratio	-0.01	-0.01	-0.01	-0.02	-0.43	-0.03	-	-	-	-
Quick Ratio	4.82	4.82	7.70	8.50	0.81	1.21	5.30	9.61	-	-
Current Ratio	5.05	5.05	7.94	8.77	0.86	1.65	5.69	9.80	-	-
Interest Coverage	-	-	-	-	-	-	-386.86	-	-834.12	-30.35
Return on Equity (ROE)	-91.80%	-91.80%	-49.40%	-31.10%	-29.70%	-175.90%	-72.20%	-70.90%	-45.90%	-31.90%
Return on Assets (ROA)	-80.40%	-80.40%	-44.20%	-25.30%	-21.00%	-122.40%	-64.50%	-64.80%	-43.20%	-28.90%
Return on Capital (ROIC)	-133.68%	-133.68%	-60.34%	-21.43%	-305.17%	-381.94%	-80.92%	-50.06%	-60.84%	-21.35%
Earnings Yield	-90.09%	-104.31%	-119.61%	-16.51%	-26.31%	-271.84%	-22.15%	-49.03%	-20.48%	-13.25%
FCF Yield	-78.30%	-90.66%	-107.77%	-23.22%	-24.41%	-171.14%	-22.25%	-46.01%	-19.14%	-17.19%
Buyback Yield / Dilution	-1.68%	-1.68%	-101.98%	-110.35%	-360.55%	-8.29%	-76.63%	-54.26%	-13.24%	-
Total Shareholder Return	-1.68%	-1.68%	-101.98%	-110.35%	-360.55%	-8.29%	-76.63%	-54.26%	-13.24%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).